ImmunityBio (IBRX) Capital Expenditures (QoQ) (2014 - 2026)
ImmunityBio (IBRX) Capital Expenditures (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | ImmunityBio | 7.60 Bn | 7.22 Bn | 43.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.83% |
| Dec 31, 2025 | 148.32% |
| Sep 30, 2025 | -174.43% |
| Dec 31, 2024 | -305.89% |
| Sep 30, 2024 | 2.77% |
| Jun 30, 2024 | 37.51% |
| Mar 31, 2024 | 109.96% |
| Dec 31, 2023 | -109.29% |
| Sep 30, 2023 | -191.10% |
| Jun 30, 2023 | -110.92% |
| Mar 31, 2023 | 0.54% |
| Dec 31, 2022 | 18.80% |
| Sep 30, 2022 | -63.28% |
| Jun 30, 2022 | 43,067.33% |
| Mar 31, 2022 | 88.35% |
| Dec 31, 2021 | -234.42% |
| Sep 30, 2021 | 1,048.53% |
| Jun 30, 2021 | -101.59% |
| Mar 31, 2021 | 353.38% |
| Jun 30, 2020 | 445.23% |